CHF5074, a novel γ - Secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 20, Issue 1, 2010, Pages 159-173

  Imbimbo, Bruno P ^a   Giardino, Luciana ^b   Sivilia, Sandra ^b   Giuliani, Alessandro ^b   Gusciglio, Marco ^b   Pietrini, Vladimiro ^c   Del Giudice, Elda ^d   D'arrigo, Antonello ^d   Leon, Alberta ^d   Villetti, Gino ^b   Calzà, Laura ^b  

^a CHIESI FARMACEUTICI S P A   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Research and Innovation   (Italy)

Author keywords

Amyloid ; contextual memory; hippocampal neurogenesis; synaptophysin; secretase modulators

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHF 5074; GAMMA SECRETASE INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONDITIONING; CONTEXTUAL MEMORY DEFICIT; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; GENE MUTATION; HIPPOCAMPUS; MACROGLIA; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROBLAST; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 77954512014     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1366     Document Type: Article

References (55)

1. Lesńe S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid protein assembly in the brain impairs memory. Nature 440, 352-357.
2. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
3. Olson RE, Albright CF (2008) Recent progress in the medicinal chemistry of secretase inhibitors. Curr Top Med Chem 8, 17-33.
4. Lleo A (2008) Activity of secretase on substrates other than APP. Curr Top Med Chem 8, 9-16.
5. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic A42 independently of cyclooxygenase activity. Nature 414, 212-216.
6. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B, Walsh DM, Koo EH, Golde TE (2008) Substrate-targeting secretase modulators. Nature 453, 925-929.
7. 1-42 secretion. J Med Chem 48, 5705-5720.
8. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A (2007) 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4- yl)-cyclopropanecarboxylic acid (CHF5074), a novel γ- secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323, 822-830.
9. 1-42 lowering agents. Pharmacol Res 55, 318-328.
10. Imbimbo BP, Hutter-Paier B, Villetti V, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M (2009) CHF5074, a novel secretase modulator, attenuates brain β- amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 156, 982-993.
11. Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet- Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS (2007) The novel gamma secretase inhibitor N-[cis-4-[(4- chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]- 1,1,1- trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320, 552-558.
12. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP,Koo EH, Golde TE, Nicolle MM (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 8, 54.
13. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL (2005) Acute secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. JNeurosci 25, 8898-8902.
14. Paxinos G, Franklin KBJ (2001) The Mouse Brain in Stereotaxic Coordinates, Second Edition, Academic Press, San Diego.
15. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103, 5161-5166.
16. Saxe MD, Battaglia F,Wang JW, Malleret G, David DJ, Monckton JE, Garcia AD, Sofroniew MV, Kandel ER, Santarelli L, Hen R, Drew MR (2006) Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci USA 103, 17501-17506.
17. Adlard PA, Perreau VM, Pop V, Cotman CW (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 25, 4217-4221.
18. Pedersen WA, Flynn ER (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17, 500-506.
19. Corcoran KA, Lu Y, Turner RS, Maren S (2002) Overexpression of hTg2576 impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem 9, 243-252.
20. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW Jr (2007) Chronic dietary alphalipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28, 213-225.
21. Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E (2001) Neurogenesis in the adult is involved in the formation of trace memories. Nature 410, 372-376.
22. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA (2004) Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 101, 343-347.
23. Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ (2001) Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32, 911-926.
24. Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP (2002) Disruption of neurogenesis by amyloid betapeptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 83, 1509-1524.
25. Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, Friedrich VL Jr, Ho L, Pasinetti GM, Shioi J, Robakis NK, Elder GA (2002) Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis 10, 8-19.
26. Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG (2004) Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 127, 601-609.
27. Wang R, Dineley KT, Sweatt JD, Zheng H (2004) Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience 126, 305-312.
28. Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ (2006) Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 495, 70-83.
29. Ermini FV, Grathwohl S, Radde R, Yamaguchi M, Staufenbiel M, Palmer TD, Jucker M (2008) Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. Am J Pathol 172, 1520-1528.
30. Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA (2004) Enhanced neurogenesis in Alzheimer's disease transgenic (PDGFAPPSw, Ind) mice. Proc Natl Acad Sci USA 101, 13363-13367.
31. Yu Y, He J, Zhang Y, Luo H, Zhu S, Yang Y, Zhao T, Wu J, HuangY,Kong J, TanQ, LiXM(2009) Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 19, 1247-1253.
32. Rao MS, Shetty AK(2004) Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci 19, 234-246.
33. Thiel G (1993) Synapsin I, synapsin II, and synaptophysin: marker proteins of synaptic vesicles. Brain Pathol 3, 87-95.
34. Hiscock JJ, Murphy S,Willoughby JO (2000) Confocal microscopic estimation of GABAergic nerve terminals in the central nervous system. J Neurosci Meth 95, 1-11.
35. DeKosky ST, Scheff SW(1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27, 457-464.
36. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
37. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel Jr DW, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56, 127-129.
38. Rutten BP, Van der Kolk NM, Schafer S, van Zandvoort MA, Bayer TA, Steinbusch HW, Schmitz C (2005) Agerelated loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol 167, 161-173.
39. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APPSw transgenic mice develop age-related A deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56, 965-973.
40. King DL, Arendash GW (2002) Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res 926, 58-68.
41. Unger C, Svedberg MM, Yu WF, Hedberg MM, Nordberg A (2006) Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (Tg2576) transgenic mice. J Pharmacol Exp Ther 317, 30-36.
42. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25, 7278-7287.
43. Dong H, Martin MV, Chambers S, Csernansky JG (2007) Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J Comp Neurol 500, 311-321.
44. Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT (2004) Cortical synaptic integration in vivo is disrupted by amyloid plaques. J Neurosci 24, 4535-4540.
45. Karlnoski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, Li Q, Gordon MN, Gottschall PE, MorganD (2009) Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J Neurosci 29, 4964-4971.
46. Cummings BJ, Mason, AJ, Kim RC, Sheu PC, Anderson AJ (2002) Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging 23, 161-170.
47. D'Andrea MR, Reiser PA, Polkovitch DA, Gumula NA, Branchide B, Hertzog, BM, Schmidheiser D, Belkowski S, Gastard MC, Andrade-Gordon P (2003) The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett 342, 114-118.
48. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C (2005) Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167, 527-543.
49. Farfara D, Lifshitz V, Frenkel D (2008) Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 12, 762-780.
50. Maragakis NJ, Rothstein JD (2006) Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2, 679-689.
51. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9, 453-457.
52. Nielsen HM,Veerhuis R, Holmqvist B, Janciauskiene S (2009) Binding and uptake of A beta 1-42 by primary human astrocytes in vitro. Glia 57, 978-988.
53. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ (2009) Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211-1215.
54. Wegiel J, Wang KC, Imaki H, Rubenstein R, Wronska A, Osuchowski M, Lipinski WJ, Walker LC, LeVine H (2001) The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol Aging 22, 49-61.
55. Lichtenstein M, Carriba P, Baltrons MA,Wojciak-Stothard B, Peterson JR, García A, Galea E (2009) Secretase-independent and Rho GTPase-dependent regulation of cytoskeleton dynamics in astrocytes by ibuprofen and derivatives. XIII Congreso of the Sociedad Espanola de Neurociencia, Tarragona, Spain, September 16-19, p. 139.